Welcome
Support Centre
17 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
'Prehab' or 'Rehab'? Minimising the loss of lean body mass after curative gastrointestinal resection and speeding rehabilitation by exercise and optimised nutrition
ISRCTN ISRCTN17506204
ClinicalTrials.gov identifier
Public title 'Prehab' or 'Rehab'? Minimising the loss of lean body mass after curative gastrointestinal resection and speeding rehabilitation by exercise and optimised nutrition
Scientific title
Acronym N/A
Serial number at source N0077170542
Study hypothesis To determine if patients scheduled for a curative resection of a gastrointestinal tumour are able to overcome the demands of surgery and metabolic derangements associated with it, more easily, following an optimized nutrition and resistance training programme. The expediated rehabilitation will be judged by body composition, cardiovascular and muscle function and anabolic responses of muscle and whole body protein metabolism. They will be compared with patients receiving only the current best standard care.
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Cancer: Gastrointestinal
Participants - inclusion criteria During a routine NHS visit 76 patients who have been identified as suitable patients at multidisciplinary team (MDT) meetings and are agreeable to participating will receive informed consent.

Inclusion Criteria: patients with curative colonic cancer.
Participants - exclusion criteria 1. Metastatic disease
2. Too weak to manage the exercise
3. Unable to give informed consent
4. Patients with insufficient command of the English language
5. Patients taking steroids or betablockers
Anticipated start date 01/11/2005
Anticipated end date 01/10/2006
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 76
Interventions During a routine NHS 76 patients who have been identified as suitable patients at MDT meetings and are agreeable to participating will receive informed consent. Screening investigations will be performed.
Patients will be randomised into two groups; a treatment group and a control group. The treatment group will enter into an eight week fitness regimen consisting of resistance exercises for twenty minutes three times a week followed by a high energy/ high protein food bar.
The control group will receive advice on nutrition and exercise alone.
There will be two study days for all patients in the study. These will be separated and may be either pre and post intervention of pre and post operative.
On each study day DEXA scanning will be performed and fractional synthetic rate determined in fasted and fed states.
All subjects will attend 7 days after their last acute study. A general examination will be performed with particular attention pain to sites of cannulation and muscle biopsies.
Recent similar studies have attracted large numbers of patients, suggesting that they will be recruitable. Opinions from patients with gastrointestinal cancer have been obtained regarding the study design and information sheets.
Primary outcome measure(s) Difference in factional synthetic rate as determined by incorporation of leucine and D%-Phenyalanine between treatment group and control group. Quantification of NFf>>B expression, mTOR and p70S6 kinase phosphorylation and protein expression in muscle samples by western analysis.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Derby Hospitals NHS Foundation Trust (UK), NHS R&D Support Funding
Trial website
Publications
Contact name Prof  M  Larvin
  Address Southern Derbyshire Acute Hospitals NHS Trust - DCGH
Derby City General Hospital
Uttoxeter Road
  City/town Derby
  Zip/Postcode DE22 3NE
  Country United Kingdom
Sponsor Record Provided by the NHSTCT Register - 2006 Update - Department of Health
  Address The Department of Health, Richmond House, 79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 29/09/2006
Last edited 11/04/2012
Date ISRCTN assigned 29/09/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central